EXHIBIT A

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	tion Act of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitute for form 1445/1-10		Application Number	10/621,027		
INFORMATION	DISCLOSURE	Filing Date	July 16, 2003		
STATEMENT BY	/ APPLICANT	First Named Inventor	CHEUNG, Nai-Kong V.		
(Use as many sheet	s as necessary)	Art Unit	1623		
lose as many since	a as necessary)	Examiner Name	Eric Olson		
Sheet 1	of 2	Attorney Docket Number	639-B-PCT-US		

	T a	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	ENGSTAD and RAA, 1999, "Immune-stimulation improving health and performance," Feed Magazine (Kraftfutter) 7-8, 261-266	
	2	FURUE et al., 1985, "Clinical evaluation of schizophyllen (SPG)in advanced gastric cancer (the second report): a randomized controlled study," Gan To Kagaku Ryoho, 12: 1272-1277 (with English abstract)	
	3	HERRE et al., February 2004, "Dectin-1 and its role in the recognition of β-glucans by macrophages," Mol. Immunol. 40(12):869-876	
	4	KERNODLE et al., March 1998, "Prophylactic Anti-infective Activity of Poh-[1-6]-B-D-Glucopyanosy4[1-5]-D-Glucopyanose Glucan in a Guinea Pig Model of Staphylococcal Wound infection," Antimicrobial Agents and Chemöhrerpa, 42(3):545-549	
	5	MAYELL M, February 2001, "Maitake Extracts and Their Therapeutic Potential – A Review," Altern. Med. Rev., 6(1):48-60	
	6	NAKAO et al., 1983, "Clinical evaluation of schizophylian (SPG) in advanced gastric cancer-a randomized comparative study by an envelope method," Gan To Kageku Ryoho, 10. 1146-1159 (with English abstract)	
	7	NAKAZATO et al., 1994, "Efficacy of immunotherapy as adjuvant treatment after curative resection of gastric cancer," The Lancet, 343:1122-1126	
	8	NICOLOSI et al., 1999, "Plasma lipid changes after supplementation with β-glucan fiber from yeast," Am. J. Clin. Nutr., 70:208-212	
	9	SELJELID et al., 1986, "A water soluble aminated §-1,3-D-glucose derivative caused regression of solid tumors In mice", Bloscience Reports 6:845-852	
	10	TORISU et al., 1990, "Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer," Cancer Immunology Immunotherapy, 31 (5):261-288	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consistence includes copy of the storm with next commissions to displace to the control of the storm with next commissions of the storm with next control of the storm with the storm with the storm of the storm with the storm of the storm o

PTO/SB/08B (02-03)

Approved for use through 04/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
Gasanas io ioni 1443/110				Application Number	10/621,027
INFORMATION DISCLOSURE				Filing Date	July 16, 2003
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	CHEUNG, Nai-Kong V.
(Use as many sheets as necessary)				Art Unit	1623
(Ose as many sneets as necessary)			ecessary	Examiner Name	Eric Olson
Sheet	2	of	2	Attorney Docket Number	639-B-PCT-US

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	WILLIAMS et al., 1991, "Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae," Immunopharmacology 22:139-155	
		,	

Examiner	Date	
Signature	Considered	

EXAMMER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through ditation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consistent. Include copy of this form with next communication to applicant.

1 Applicants union claims designation member (optional). Applicants into 10 stoce a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 U.S. C. 12 and 37 CPR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case, Any commonts on the amount of time by create to complete the form and/or suggestions for reducing this burden, though to sent in the Chef information Officer, U.S. Pepariment of Commence, Washington, DC 20231, DO NOT SEND FEES OR QUARLETED FORMS TO THIS ADDRESS. SEND TO-Commission for Prations, Washington, DC 20231.